Pembrolizumab plus Lenvatinib

DRUG2 trials

Sponsors

Tianjin Medical University Second Hospital, National Cancer Center, Japan

Conditions

Angiosarcoma MetastaticAngiosarcoma of SkinRenal Cell Carcinoma

Phase 2

Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC

CompletedNCT05485896

Tianjin Medical University Second HospitalRenal Cell Carcinoma

Start: 2022-07-01End: 2024-09-02Updated: 2024-09-19

Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients

RecruitingNCT06673628

National Cancer Center, JapanAngiosarcoma Metastatic, Angiosarcoma of Skin

Start: 2024-12-01End: 2029-11-30Target: 38Updated: 2026-06-24

Related Papers

The phase II study of pembrolizumab plus lenvatinib for patients with unresectable cutaneous angiosarcoma (Pembro-Lenva for cAS/PLAS trial).

Journal of Clinical Oncology2025-05-28

Neoadjuvant lenvatinib plus pembrolizumab for resectable clear-cell renal cell carcinoma (PELUR): A prospective phase 2 study.

Journal of Clinical Oncology2025-05-28